Literature DB >> 27780835

Developmental Changes in Hepatic Organic Cation Transporter OCT1 Protein Expression from Neonates to Children.

David Hahn1, Chie Emoto1, Alexander A Vinks1, Tsuyoshi Fukuda2.   

Abstract

Organic cation transporter 1 (OCT1) plays an important role in the disposition of clinically important drugs, and the capacity of OCT1 activity is presumed to be proportional to the protein expression level in organ tissues. Knowledge of OCT1 protein expression in children, especially neonates and small infants, is currently very limited. Here, we report on the characterization of OCT1 protein expression in neonatal, infant, and pediatric liver samples performed using immunoblot analysis. OCT1 protein expression was detected in liver samples from neonates as early as postnatal days 1 and 2. This youngest group showed significantly lower OCT1 expression normalized by glyceraldehyde-6-phosphate dehydrogenase (values given as means ± S.D. in arbitrary units; 0.03 ± 0.02, n = 7) compared with samples from patients aged 3 to 4 weeks (0.08 ± 0.03, n = 5, P < 0.01), 3 to 6 months (0.23 ± 0.15, n = 7, P < 0.01), 11 months to 1 year (0.42 ± 0.32, n = 6, P < 0.01), and 8 to 12 years (1.00 ± 0.44, n = 7, P < 0.01). These data demonstrate an age-dependent increase in OCT1 expression from birth up to 8 to 12 years of age, and the findings of this study contribute to the understanding of OCT1 functional capacity and its effect upon the disposition of OCT1 substrates in neonates and small infants.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27780835      PMCID: PMC6047210          DOI: 10.1124/dmd.116.072256

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  14 in total

1.  Fiji: an open-source platform for biological-image analysis.

Authors:  Johannes Schindelin; Ignacio Arganda-Carreras; Erwin Frise; Verena Kaynig; Mark Longair; Tobias Pietzsch; Stephan Preibisch; Curtis Rueden; Stephan Saalfeld; Benjamin Schmid; Jean-Yves Tinevez; Daniel James White; Volker Hartenstein; Kevin Eliceiri; Pavel Tomancak; Albert Cardona
Journal:  Nat Methods       Date:  2012-06-28       Impact factor: 28.547

2.  Morphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administration.

Authors:  Mladen V Tzvetkov; Joao N dos Santos Pereira; Ingolf Meineke; Ali R Saadatmand; Julia C Stingl; Jürgen Brockmöller
Journal:  Biochem Pharmacol       Date:  2013-07-05       Impact factor: 5.858

3.  Human organic cation transporters 1 (SLC22A1), 2 (SLC22A2), and 3 (SLC22A3) as disposition pathways for fluoroquinolone antimicrobials.

Authors:  Aditi Mulgaonkar; Jürgen Venitz; Dirk Gründemann; Douglas H Sweet
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

4.  OCT1 genetic variants influence the pharmacokinetics of morphine in children.

Authors:  Tsuyoshi Fukuda; Vidya Chidambaran; Tomoyuki Mizuno; Raja Venkatasubramanian; Pornswan Ngamprasertwong; Vanessa Olbrecht; Hope R Esslinger; Alexander A Vinks; Senthilkumar Sadhasivam
Journal:  Pharmacogenomics       Date:  2013-07       Impact factor: 2.533

5.  Organic cation transporters are determinants of oxaliplatin cytotoxicity.

Authors:  Shuzhong Zhang; Katherine S Lovejoy; James E Shima; Leah L Lagpacan; Yan Shu; Anna Lapuk; Ying Chen; Takafumi Komori; Joe W Gray; Xin Chen; Stephen J Lippard; Kathleen M Giacomini
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

6.  Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins.

Authors:  Hiroaki Kimura; Michio Takeda; Shinichi Narikawa; Atsushi Enomoto; Kimiyoshi Ichida; Hitoshi Endou
Journal:  J Pharmacol Exp Ther       Date:  2002-04       Impact factor: 4.030

7.  Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.

Authors:  Anne T Nies; Hermann Koepsell; Stefan Winter; Oliver Burk; Kathrin Klein; Reinhold Kerb; Ulrich M Zanger; Dietrich Keppler; Matthias Schwab; Elke Schaeffeler
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

8.  Functional involvement of organic cation transporter1 (OCT1/Oct1) in the hepatic uptake of organic cations in humans and rats.

Authors:  K-I Umehara; T Iwatsubo; K Noguchi; H Kamimura
Journal:  Xenobiotica       Date:  2007-08       Impact factor: 1.908

Review 9.  Xenobiotic, bile acid, and cholesterol transporters: function and regulation.

Authors:  Curtis D Klaassen; Lauren M Aleksunes
Journal:  Pharmacol Rev       Date:  2010-01-26       Impact factor: 25.468

Review 10.  Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications.

Authors:  Hermann Koepsell; Katrin Lips; Christopher Volk
Journal:  Pharm Res       Date:  2007-05-01       Impact factor: 4.580

View more
  5 in total

Review 1.  Incorporating Ontogeny in Physiologically Based Pharmacokinetic Modeling to Improve Pediatric Drug Development: What We Know About Developmental Changes in Membrane Transporters.

Authors:  Kit Wun Kathy Cheung; Bianca D van Groen; Gilbert J Burckart; Lei Zhang; Saskia N de Wildt; Shiew-Mei Huang
Journal:  J Clin Pharmacol       Date:  2019-09       Impact factor: 3.126

Review 2.  Recent advances in the ontogeny of drug disposition.

Authors:  Brian D Chapron; Alenka Chapron; J Steven Leeder
Journal:  Br J Clin Pharmacol       Date:  2021-04-15       Impact factor: 3.716

3.  Ontogeny-related pharmacogene changes in the pediatric liver transcriptome.

Authors:  Richard Meier; Chengpeng Bi; Roger Gaedigk; Daniel P Heruth; Shui Qing Ye; J Steven Leeder; Brooke L Fridley
Journal:  Pharmacogenet Genomics       Date:  2018-03       Impact factor: 2.089

4.  PBPK Model of Morphine Incorporating Developmental Changes in Hepatic OCT1 and UGT2B7 Proteins to Explain the Variability in Clearances in Neonates and Small Infants.

Authors:  Chie Emoto; Trevor N Johnson; Sibylle Neuhoff; David Hahn; Alexander A Vinks; Tsuyoshi Fukuda
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2018-06-19

5.  VARIDT 2.0: structural variability of drug transporter.

Authors:  Tingting Fu; Fengcheng Li; Yang Zhang; Jiayi Yin; Wenqi Qiu; Xuedong Li; Xingang Liu; Wenwen Xin; Chengzhao Wang; Lushan Yu; Jianqing Gao; Qingchuan Zheng; Su Zeng; Feng Zhu
Journal:  Nucleic Acids Res       Date:  2022-01-07       Impact factor: 16.971

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.